ReNeuron Group (ReNeuron Group) Notes Receivable : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Notes Receivable?

ReNeuron Group's Notes Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

ReNeuron Group Notes Receivable Historical Data

The historical data trend for ReNeuron Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Notes Receivable Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Notes Receivable

Get a 7-Day Free Trial

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

ReNeuron Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

ReNeuron Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.